6. Pernix Therapeutics Holdings (PTX - Get Report) a specialty pharmaceutical company, is mainly focused on developing and commercializing pharmaceutical products in order to meet unmet medical needs primarily in pediatrics. Through a combination of internal development, acquisition and in-licensing activities, the company develops and promotes its products in almost 30 states.
Net income for the first quarter 2011 is forecast at $1.99 million on sales of $8.5 million, compared to net income of $1.49 million on $12.2 million sales recorded during 2010 fourth quarter, according to analysts polled by Bloomberg. Earnings per share are seen at 10 cents for the quarter, up from 6 cents per share reported during fourth quarter of 2010.
Both the analysts covering the stock recommend a buy rating on it. There are no sell ratings on the stock. Analysts polled by Bloomberg expect the stock to gain an average 65.3% to $20.5 in value from current levels.